DXSP DXS International PLC

DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meeting

DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meeting

Monday 24 November

DXS INTERNATIONAL PLC (AQSE: DXSP)

Notice of 2025 Annual General Meeting

The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that its Annual General Meeting is scheduled to take place on Thursday 18th December at 11.30 at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB.

For further information in relation to the AGM, shareholders should refer to the Notice of Annual General Meeting and the AGM Letter which have been despatched to shareholders. Copies of these documents, along with the Company's Annual Report for the year ended 30 April 2025, are available for download from the Company's website

The Directors of DXS International plc accept responsibility for this announcement. This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

Contacts:

David Immelman



DXS International plc



-systems.com



 
01252 719800
AQSE Corporate Broker and Corporate Advisor



Hybridan LLP



Claire Louise Noyce
 



020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.



EN
24/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DXS International PLC

 PRESS RELEASE

DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meet...

DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meeting Monday 24 November DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of 2025 Annual General Meeting The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that its Annual General Meeting is scheduled to take place on Thursday 18th December at 11.30 at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB. For further information in relation to the AGM, shareholders should...

 PRESS RELEASE

DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dea...

DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 11 November, Mr Bob Sutcliffe, the Chairman, purchased 50,000 Ordinary Shares in the Company at a price of 1.30p per share. Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Research: DXS International plc: NHS Opportunity Remains

Despite bureaucratic headaches, the final results to 30 April report a 5% increase in revenue to £3.5m and a reduced loss to £94.8k. The P&L comparison with 2024 is awkward due to changes in accounting practises and the £4.7m impairment charge. The FY 2025 loss was affected by a sharp decline in allowable R&D which was down to £80k from £212k due to HMRC’s new restrictions on overseas development. DXS continues to significantly invest in innovation and developing solutions. These costs are now ...

 PRESS RELEASE

DXS International plc ((AQSE: DXSP) - Final Results

DXS International plc ((AQSE: DXSP) - Final Results DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 30 April 2025 The Board of DXS International plc (“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2025. Financial highlights: Revenue increased by 5% to £3,469,917 (2024: £3,308,359). Core recurring revenue model remains resilient.Available cash at the period end was £428,957 plus unutilised debtor drawdowns of £2...

 PRESS RELEASE

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK ...

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK Research Project DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare featured in Innovate UK Research Project DXS International plc ("DXS" or "the Company"), a leading provider of digital clinical decision support solutions, is thrilled to announce that its leading-edge digital health solution, ExpertCare, has been independently reviewed by the prestigious York Health Economics Consortium (YHEC) with results that confirm its powerful impact on both clinical outcomes and NHS cost-efficiency.  Funded by DXS and Innovate UK and...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch